W2O acquires med comms agency Arcus Medica
Healthcare marketing communications agency W2O has acquired Philadelphia’s Arcus Medica to boost its scientific and med comms offering.
W2O said the combination would create a fully-integrated communications agency and disrupt the medical and scientific communications status quo through the use of proprietary data and analytics.
The agency’s founder and CEO Jim Weiss said: “Arcus is a trailblazer in the field of medical and scientific communications, consistently following the data to get to the right outcome for its clients. The addition of Arcus to the W2O family significantly enhances our medical and scientific communications expertise and enriches our offering in this key discipline.
“Together, we will continue to place science at the centre of everything we do, supplementing this prowess with unmatched data analytics and insights, robust strategy and creative know-how to ensure we deliver maximum impact to client business, from the bench to the bedside.”
Arcus co-founders Mary Seideman, Stan Eapen and Jonathan Seideman will all serve in leadership roles at the healthcare communications agency, which will be renamed W2O Arcus, where they will work closely with the wider scientific strategy team at W2O that’s run by Ujwal Pyati.
Seideman said: “We founded Arcus on the premise of serving as strategic partners to our clients by providing world-class communications attuned to the unique challenges of the healthcare market. We couldn’t be more excited about our affiliation with W2O, given Jim and his team’s commitment to becoming the best by understanding every client’s business and treating it as its own.”
For W2O the acquisition of Arcus follows its partnership with the New York-based investment firm New Mountain Capital to support its growth and accelerate the scaling of its business.
Weiss added: “Integrating Arcus’ scientific and medical communications capability into our expansive, multidisciplinary service offering will ensure we are more competitively positioned and favoured in the healthcare communications marketplace.”
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.